Briacell Therap (NASDAQ:BCTX) Raised to Sell at Wall Street Zen

Briacell Therap (NASDAQ:BCTX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Briacell Therap currently has a consensus rating of “Sell”.

Briacell Therap Stock Performance

NASDAQ:BCTX opened at $3.88 on Friday. The stock has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $7.07. Briacell Therap has a 52-week low of $3.60 and a 52-week high of $53.80. The firm has a market capitalization of $28.13 million, a PE ratio of -0.17 and a beta of 1.30.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new position in Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap at the end of the most recent quarter. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.